Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.41 |
| ▸ | TUBB | P07437 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14236166 | 0.86 | KDM4E (0.47) | MAPTRAB9AKMT2ANPSR1LMNA | |
| SCHEMBL19125086 | 0.83 | SLC5A1 (0.54) | MAPTRAB9AKMT2ANPSR1MEN1 | |
| SCHEMBL14235747 | 0.81 | MAPT (0.45) | MAPTRAB9AKMT2AMEN1LMNA | |
| SCHEMBL27454175 | 0.77 | MAPT (0.57) | MAPTRAB9AKMT2ANPSR1MEN1 | |
| SCHEMBL23221118 | 0.74 | NPC1 (0.60) | MAPTRAB9AKMT2ANPSR1MEN1 | |
| SCHEMBL11575471 | 0.73 | KMT2A (0.66) | MAPTRAB9AKMT2ANPSR1MEN1 | |
| SCHEMBL15610574 | 0.72 | SLC5A2 (0.56) | SLC5A1SLC5A2 | |
| SCHEMBL14128389 | 0.71 | SMN1; SMN2 (0.40) | KMT2ANPSR1MEN1RXFP1HTT | |
| SCHEMBL6380377 | 0.71 | MAPT (0.57) | MAPTRAB9AKMT2ANPSR1MEN1 | |
| SCHEMBL8483054 | 0.71 | MAPT (0.67) | MAPTRAB9AKMT2ANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714032-B1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORP (KR) | 2019-01-16 | — | — | EP | disclosed |
| EP-2714032-B1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORP (KR) | 2019-01-16 | — | — | EP | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-9371303-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2016-06-21 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2015-06-04 | — | — | US | disclosed |
| US-9034921-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2015-05-19 | — | — | US | disclosed |
| US-9034921-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2015-05-19 | — | — | US | disclosed |
| US-9034921-B2 | Diphenylmethane derivatives as SGLT2 inhibitors | GREEN CROSS CORPORATION (KR) | 2015-05-19 | — | — | US | disclosed |
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-03-27 | — | — | US | disclosed |
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-03-27 | — | — | US | disclosed |
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORPORATION (KR) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088079-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | MAPT 1050/4885RAB9A 3188/4885KMT2A 974/4885 |
| US-20150152075-A1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | SLC5A2, SLC5A1, SLC2A8 | MAPT 910/4885RAB9A 2951/4885KMT2A 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.